Last reviewed · How we verify
AK104 plus Carboplatin and paclitaxel
AK104 plus Carboplatin and paclitaxel is a Small molecule drug developed by Akeso. It is currently in Phase 1 development.
At a glance
| Generic name | AK104 plus Carboplatin and paclitaxel |
|---|---|
| Sponsor | Akeso |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer (PHASE1, PHASE2)
- A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer (PHASE3)
- SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) (PHASE2)
- A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer (PHASE2)
- Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer (PHASE3)
- Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma (PHASE2)
- A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE1, PHASE2)
- AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK104 plus Carboplatin and paclitaxel CI brief — competitive landscape report
- AK104 plus Carboplatin and paclitaxel updates RSS · CI watch RSS
- Akeso portfolio CI
Frequently asked questions about AK104 plus Carboplatin and paclitaxel
What is AK104 plus Carboplatin and paclitaxel?
AK104 plus Carboplatin and paclitaxel is a Small molecule drug developed by Akeso.
Who makes AK104 plus Carboplatin and paclitaxel?
AK104 plus Carboplatin and paclitaxel is developed by Akeso (see full Akeso pipeline at /company/akeso).
What development phase is AK104 plus Carboplatin and paclitaxel in?
AK104 plus Carboplatin and paclitaxel is in Phase 1.
Related
- Manufacturer: Akeso — full pipeline
- Compare: AK104 plus Carboplatin and paclitaxel vs similar drugs
- Pricing: AK104 plus Carboplatin and paclitaxel cost, discount & access